Skip to main content
SpringerLink
Log in

Statins and Nutraceuticals/Functional Food: Could They Be Combined?

  • Chapter
Combination Therapy In Dyslipidemia

Abstract

Hypercholesterolemia constitutes one of the main cardiovascular risk factors and, consequently, treat it is really important to limit the risk of one of the leading causes of death in developed countries.

Therefore, an effective treatment to reduce high cholesterol is necessary: statins have proved to be the gold standard among lipid-lowering drugs, but at the cost of many unpleasant side effects.

At the same time, many nutraceuticals or functional foods were identified to lower levels of LDL cholesterol, acting according to different mechanisms of action.

Soluble fiber, glucomannan, plant sterols and probiotics inhibit the absorption of cholesterol and biliary salts by the bowel; monacolins, polycosanols, garlic and bergamot inhibit HMG-CoA reductase, limiting the hepatic synthesis of cholesterol; berberine, soy proteins and green tea act as inducers of LDL cholesterol excretion.

Clinical trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects.

The results of the studies carried out have been encouraging, but further clinical trials prolonged over time are required to better assess the potential and possible long-term side effects of nutraceuticals and their combination with statins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ackermann RT, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813–24.

    Article  CAS  PubMed  Google Scholar 

  2. Affuso F, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4:77–83.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Anderson GD, et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003;43:643–8.

    Article  PubMed  Google Scholar 

  4. Anderson JW, et al. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276–82.

    Article  CAS  PubMed  Google Scholar 

  5. Berginc K, et al. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet. 2010;25(6):521–30.

    Article  CAS  PubMed  Google Scholar 

  6. Berthold HK, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized, controlled trial. JAMA. 2006;295:2262–9.

    Article  CAS  PubMed  Google Scholar 

  7. Brashears MM, et al. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998;81:2103–10.

    Article  CAS  PubMed  Google Scholar 

  8. Burcelin R, et al. The gut microbiota ecology: new opportunity for the treatment of metabolic diseases? Front Biosci. 2009;14:5107–17.

    Article  CAS  Google Scholar 

  9. Cambria-Kiely JA. Effect of soy milk on warfarin. Ann Pharmacother. 2002;36:1893–6.

    Article  PubMed  Google Scholar 

  10. Cani PD, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonat. 1993;63:201–8.

    Article  CAS  Google Scholar 

  12. Chen ST, et al. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis. 2005;46:1099–106.

    Article  CAS  PubMed  Google Scholar 

  13. Chua M, et al. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol. 2010;128:268–78.

    Article  PubMed  Google Scholar 

  14. Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol. 2009;4(5):553–63.

    Article  CAS  Google Scholar 

  15. Cicero AFG, et al. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med. 2005;13:273–8.

    Article  PubMed  Google Scholar 

  16. Cicero AFG, et al. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung. 2007;57:26–30.

    CAS  PubMed  Google Scholar 

  17. Cicero AFG, et al. Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients. Nutrafoods. 2012;11(2):15–21.

    Article  Google Scholar 

  18. Cicero AFG, et al. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf. 2012;11(5):753–66. doi:10.1517/14740338.2012.705827.

    Article  CAS  PubMed  Google Scholar 

  19. Cicero AFG, et al. Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercholesterolemic patients with or without chronic kidney disease. Open Hypertens J. 2013;5:18–22.

    Article  CAS  Google Scholar 

  20. Cicero AFG, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res. 2013;33(8):622–8. doi:10.1016/j.nutres.2013.05.01.

    Article  CAS  PubMed  Google Scholar 

  21. Cicero AFG, et al. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol. 2014;12(4):565–71.

    Article  CAS  PubMed  Google Scholar 

  22. Cicero AFG, et al. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev. 2014;21(3):221–6. doi:10.1007/s40292-014-0052-5.

    Article  CAS  PubMed  Google Scholar 

  23. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev. 2007;25(4):375–90.

    CAS  PubMed  Google Scholar 

  24. Derosa G, et al. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113–24.

    Article  CAS  PubMed  Google Scholar 

  25. Eisenbrand G. Toxicological evaluation of red mould rice. Mol Nutr Food Res. 2006;50:322–7.

    Article  CAS  PubMed  Google Scholar 

  26. El Khoury D, Anderson GH. Recent advances in dietary proteins and lipid metabolism. Curr Opin Lipidol. 2013;24(3):207–13. doi:10.1097/MOL.0b013e3283613bb7.

    Article  PubMed  Google Scholar 

  27. Gheit O, et al. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Eur J Intern Med. 2009;20:e57–61.

    Article  Google Scholar 

  28. Gliozzi M, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140–5. doi:10.1016/j.ijcard.2013.08.125.

    Article  PubMed  Google Scholar 

  29. Grieco A, et al. A cute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all. J Hepatol. 2009;50:1273–7.

    Article  PubMed  Google Scholar 

  30. Grill JP, et al. Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol. Lett Appl Microbiol. 2000;31:154–6.

    Article  CAS  PubMed  Google Scholar 

  31. Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol. 2005;96(suppl):47D–50.

    Article  CAS  PubMed  Google Scholar 

  32. Guardamagna O, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol. 2011;48:127–33.

    Article  CAS  PubMed  Google Scholar 

  33. Guo Z, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844–50.

    Article  CAS  PubMed  Google Scholar 

  34. Gylling H, et al. The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat soluble vitamins. Clin Nutr. 2010;29:112–8.

    Article  CAS  PubMed  Google Scholar 

  35. Gylling H, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346–60. doi:10.1016/j.atherosclerosis.2013.11.043.

    Article  CAS  PubMed  Google Scholar 

  36. Halbert SC, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105(2):198–204.

    Article  CAS  PubMed  Google Scholar 

  37. Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis. 2008;200:13–27.

    Article  CAS  PubMed  Google Scholar 

  38. Hutchins AM, et al. Hypertensive crisis associated with high dose soy isoflovane supplementation in a post-menopausal woman; a case report. BMC Womens Health. 2005;5:9.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. A systematic review. Drugs. 2001;61:2163–75.

    Article  CAS  PubMed  Google Scholar 

  40. Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol. 2009;157:1354–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30–4.

    PubMed  Google Scholar 

  42. Keithley J, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18:201–4.

    Article  CAS  PubMed  Google Scholar 

  43. Klaver FA, Van der Meer V. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt –deconjugating activity. Appl Environ Microbiol. 1993;59:1120–4.

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Kim A, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc. 2011;111:1720–9.

    Article  CAS  PubMed  Google Scholar 

  45. Kong W, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–51.

    Article  CAS  PubMed  Google Scholar 

  46. Kumar M, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Kwak JS, et al. Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials. Nutr Res Pract. 2014;8(6):644–54. doi:10.4162/nrp.2014.8.6.644.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Lenz TL. Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipidemias in adults. J Am Pharm Assoc. 2005;45(4):492–9.

    Article  Google Scholar 

  49. Li G, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol. 2012;258(2):268–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Lin YL, et al. Biologically active components and nutraceuticals in Monascus-fermented rice: a review. Appl Microbiol Biotechnol. 2008;77:965–73.

    Article  CAS  PubMed  Google Scholar 

  51. Liu J, et al. Chinese red yeast rice (monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Liu ZL, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011;(7):CD008305.

    Google Scholar 

  53. Macan H, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(3 Suppl):793S–5.

    CAS  PubMed  Google Scholar 

  54. Maciejko JJ, et al. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. Arch Fam Med. 1994;3:955–60.

    Article  CAS  PubMed  Google Scholar 

  55. Mannarino MR, et al. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med. 2014;25(7):592–9. doi:10.1016/j.ejim.2014.06.008.

    Article  CAS  PubMed  Google Scholar 

  56. Marinangeli CP, et al. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr. 2010;50:259–67.

    Article  CAS  PubMed  Google Scholar 

  57. Martino F, et al. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis. 2005;15:174–80.

    Article  PubMed  Google Scholar 

  58. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002;58(6):487–90.

    Article  CAS  PubMed  Google Scholar 

  59. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep. 2009;11:470–6.

    Article  CAS  PubMed  Google Scholar 

  60. Mechanick JI, et al. AACE Nutrition Guidelines Taskforce. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract. 2003;9:417–70.

    Article  PubMed  Google Scholar 

  61. Mensink RP, et al. Plant stenols dose dependently decrease LDL cholesterol concentrations but not cholesterol standardized fat soluble antioxidant concentrations, at intakes up to 9g/d. Am J Clin Nutr. 2010;92:24–33.

    Article  CAS  PubMed  Google Scholar 

  62. Mogadishian MH, et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999;99:1733–9.

    Article  Google Scholar 

  63. Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamotpolyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309–16. doi:10.1016/j.fitote.2010.10.014.

    Article  CAS  PubMed  Google Scholar 

  64. Moreyra AE, et al. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161–6.

    Article  CAS  PubMed  Google Scholar 

  65. Morgan LM, et al. The effect of soluble- and insoluble-fibre supplementation on post-prandial glucose tolerance, insulin and gastric inhibitory polypeptide secretion in healthy subjects. Br J Nutr. 1990;64:103–10.

    Article  CAS  PubMed  Google Scholar 

  66. Moruisi KG, et al. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25:41–8.

    Article  CAS  PubMed  Google Scholar 

  67. Mullen E, et al. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr. 2004;134:2942–7.

    CAS  PubMed  Google Scholar 

  68. Nijjar PS, et al. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4(4):248–58.

    Article  PubMed  Google Scholar 

  69. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr. 1995;125(3 Suppl):606S–11.

    CAS  PubMed  Google Scholar 

  70. Ras RT, et al. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–9. doi:10.1017/S0007114514000750.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Ried K, et al. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282–99. doi:10.1111/nure.12012.

    Article  PubMed  Google Scholar 

  72. Samman S, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr. 2001;73:607–12.

    CAS  PubMed  Google Scholar 

  73. Scholle JM, et al. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J Am Coll Nutr. 2009;28:517–24.

    Article  CAS  PubMed  Google Scholar 

  74. Shirashi M, et al. Association between serum folate levels and tea consumption during pregnancy. Biosci Trends. 2010;4:225–30.

    Google Scholar 

  75. Shrestha S, et al. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137:1165–70.

    CAS  PubMed  Google Scholar 

  76. Singh DK, et al. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318:1020–6.

    Article  CAS  PubMed  Google Scholar 

  77. Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep. 2001;3:47–53.

    Article  CAS  PubMed  Google Scholar 

  78. Sood N, et al. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008; 88(4):1167–75.

    CAS  PubMed  Google Scholar 

  79. Stock J. Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods. Atherosclerosis. 2014;234(1):142–5. doi:10.1016/j.atherosclerosis.2014.01.047.

    Article  CAS  PubMed  Google Scholar 

  80. Tokunaga S, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol. 2002;12:157–65.

    Article  PubMed  Google Scholar 

  81. Torres N, et al. Regulation of lipid metabolism by soyprotein and its implication in diseases mediated by lipid disorders. J Nutr Biochem. 2006;17:365–73.

    Article  CAS  PubMed  Google Scholar 

  82. Trimarco B, et al. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab. 2011;4:133–40.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Vega-López S, et al. Sex and hormonal status modulate the effects of psyllium on plasma lipids and monocyte gene expression in humans. J Nutr. 2003;133:67–70.

    PubMed  Google Scholar 

  84. Vergara-Jimenez M, et al. Hypolipidemic mechanisms of pectin and pysllium in guinea pigs fed high fat-sucrose diets: alterations on hepatic cholesterol metabolism. J Lipid Res. 1998;39:1455–65.

    CAS  PubMed  Google Scholar 

  85. Vrzal R, et al. Activation of the arylhydrocarbon receptor by berberine in HepG2 and H4IIEcells: Biphasic effect on CYP1A1. Biochem Pharmacol. 2005;70:925–36.

    Article  CAS  PubMed  Google Scholar 

  86. Vuksan V, et al. Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr. 2001;20(S5):370S–80.

    Article  CAS  PubMed  Google Scholar 

  87. Weghuber D, Widhalm K. Effect of 3 month treatment of children and adolescents with familial and polygenic hypercholesterolemia with a soy-substituted diet. Br J Nutr. 2008;99:281–6.

    Article  CAS  PubMed  Google Scholar 

  88. Wei ZH, et al. Time- and dose-dependent effect of psylium on serum lipids in mild- to- moderate hypercholesterolemia: a meta—analysis of controlled trials. Eur J Clin Nutr. 2009;63:821–7.

    Article  CAS  PubMed  Google Scholar 

  89. Weingärtner O, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16):1553–61.

    Article  PubMed  Google Scholar 

  90. Weingärtner O, et al. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30(4):404–9.

    Article  PubMed Central  PubMed  Google Scholar 

  91. Weingärtner O, et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE−/− mice. Cardiovasc Res. 2011;90(3):484–92.

    Article  PubMed Central  PubMed  Google Scholar 

  92. Xin HW, et al. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28:25–9.

    Article  CAS  PubMed  Google Scholar 

  93. Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr Opin Lipidol. 2008;19(3):263–9.

    Article  CAS  PubMed  Google Scholar 

  95. Zheng XX, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94:601–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Via Albertoni 15, Bologna, 40138, Italy

    Arrigo F. G. Cicero & Alessandro Colletti

Authors
  1. Arrigo F. G. Cicero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Colletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arrigo F. G. Cicero .

Editor information

Editors and Affiliations

  1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    Maciej Banach

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Cicero, A.F.G., Colletti, A. (2015). Statins and Nutraceuticals/Functional Food: Could They Be Combined?. In: Banach, M. (eds) Combination Therapy In Dyslipidemia. Adis, Cham. https://doi.org/10.1007/978-3-319-20433-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20433-8_11

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20432-1

  • Online ISBN: 978-3-319-20433-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation